Pneumococcal Vaccine Market Size Worth US$ 12.2 Billion By 2028 | Industry CAGR of 5.2%

A latest research report by IMARC group the titled is that "Pneumococcal Vaccine Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028", offers a comprehensive analysis of the industry, which comprises insights on pneumococcal vaccine market. The report also includes competitor and regional analysis, and contemporary advancements in the global market. The global pneumococcal vaccine market size reached US$ 8.9 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 12.2 Billion by 2028, exhibiting a growth rate (CAGR) of 5.2% during 2023-2028.

What are pneumococcal vaccine?

The pneumococcal vaccine is a crucial immunization that helps protect individuals against infections caused by the bacterium Streptococcus pneumoniae. It is specifically designed to prevent various pneumococcal diseases, including pneumonia, meningitis, septicemia (bloodstream infection), and otitis media (middle ear infection). It functions by stimulating the body's immune system to recognize and respond to specific components of the bacteria, known as antigens. By doing so, it promotes the production of antibodies that can effectively combat the bacteria and aid in preventing infection or reducing the severity of the disease if an infection does occur. There are different types of pneumococcal vaccines available, including the pneumococcal conjugate vaccine (PCV) and the pneumococcal polysaccharide vaccine (PPSV). PCV is primarily administered to infants and young children, while PPSV is recommended for older children, adults, and individuals at increased risk of pneumococcal diseases.

Get a Sample Copy of this Report: https://www.imarcgroup.com/pneumococcal-vaccine-market/requestsample

What are the growth prospects and trends in the pneumococcal vaccine industry?

The rising prevalence of pneumococcal disease among the masses majorly drives the global market. This can be supported by pneumococcal infections, such as pneumonia, meningitis, and septicemia, leading to a significant number of deaths and illnesses across the globe, particularly among young children, older adults, and individuals with weakened immune systems. Therefore, the growing awareness among healthcare professionals and the general public is creating a pressing need for preventive measures, such as pneumococcal vaccine. Along with this, the increasing number of immunization campaigns, especially in countries with high disease burdens due to the rising emphasis on preventive healthcare by governments and healthcare organizations, is significantly supporting the market. In addition, partnerships between governments, non-profit organizations, and vaccine manufacturers facilitating the availability of affordable pneumococcal vaccines are contributing to the market. Furthermore, the development of conjugate vaccines, which provide a more comprehensive and longer-lasting immune response, is creating a positive market outlook.

View Full Report with TOC & List of Figure: https://www.imarcgroup.com/pneumococcal-vaccine-market

Competitive Landscape:

The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.

• Astellas Pharma Inc.
• GlaxoSmithKline Plc.
• Merck & Co. Inc.
• Panacea Biotec Ltd.
• Pfizer Inc.
• Sanofi S.A.
• Serum Institute of India Pvt Ltd
• Walvax Biotechnology Co. Ltd.

Pneumococcal Vaccine Market Segmentation:

Our report has categorized the market based on region, vaccine type, product type, distribution channel and end user.

Breakup by Vaccine Type:
• Pneumococcal Conjugate Vaccine
• Pneumococcal Polysaccharide Vaccine

Breakup by Product Type:
• Prevnar 13
• Synflorix
• Pneumovax 23

Breakup by Distribution Channel:
• Distribution Partner Companies
• Non-Governmental Organizations (NGO)
• Government Authorities

Breakup by End User:
• Pediatrics
• Adults

Breakup by Region:
• North America (United States, Canada)
• Europe (Germany, France, United Kingdom, Italy, Spain, Others)
• Asia Pacific (China, Japan, India, Australia, Indonesia, Korea, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa (United Arab Emirates, Saudi Arabia, Qatar, Iraq, Other)

Key highlights of the report:
• Market Performance (2017-2022)
• Market Outlook (2023-2028)
• Porter's Five Forces Analysis
• Market Drivers and Success Factors
• SWOT Analysis
• Value Chain
• Comprehensive Mapping of the Competitive Landscape

Contact US:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe:- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise.

This release was published on openPR.